Literature DB >> 6957273

Vindesine effect in myeloid leukemia.

M Baccarani, A Zaccaria, G Corbelli, S Tura.   

Abstract

Vindesine (VDS), a semisynthetic vinca alkaloid derivative, was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy to seven patients with chronic myeloid leukemia (CML), 17 patients with chronic myeloid leukemia in blastic metamorphosis (CML/BM), and 12 patients with acute nonlymphocytic leukemia (ANLL). A substantial and rapid decrease of leukemic cells was obtained in 31 of 36 patients, and this was independent of cell phenotype and morphology. VDS may improve the results of polychemotherapy of ANLL, and is useful for palliative treatment of CML/BM.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6957273     DOI： 10.1007/bf00254046

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

Review 1.  Metamorphosis of chronic granulocytic leukaemia: diagnosis, classification, and management.

Authors:  A S Spiers
Journal:  Br J Haematol       Date:  1979-01       Impact factor: 6.998

2.  Vindesine. A short review of preclinical and first clinical data.

Authors:  R W Dyke; R L Nelson; W P Brade
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Phase II trial of vindesine in patients with malignant lymphoma.

Authors:  R B Sklaroff; D Straus; C Young
Journal:  Cancer Treat Rep       Date:  1979-05

4.  Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

Authors:  M Bayssas; J Gouveia; P Ribaud; M Musset; F de Vassal; J L Pico; L de Luca; J L Misset; D Machover; D Belpomme; L Schwarzenberg; C Jasmin; M Hayat; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Antitumor activity of deacetyl vinblastine amide sulfate (vindesine) in rodents and mitotic accumulation studies in culture.

Authors:  M J Sweeney; G B Boder; G J Cullinan; H W Culp; W D Daniels; R W Dyke; K Gerzon; R E McMahon; R L Nelson; G A Poore; G C Todd
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

6.  Phase I and II studies of vindesine.

Authors:  M Valdivieso
Journal:  Cancer Treat Rev       Date:  1980-09       Impact factor: 12.111

7.  A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.

Authors:  W Krivit; J Anderson; R Chilcote; A Pyesmany; R Chard; D Hammond
Journal:  Am J Pediatr Hematol Oncol       Date:  1980

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia.

Authors:  T S Vats; P Mehta; R C Trueworthy; S D Smith; P Klopovich
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

10.  Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial.

Authors:  J Anderson; W Krivit; R Chilcote; A Pyesmany; R Chard; D Hammond
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.